Alphabet Eyes First Australian Dollar Bond as AI Spending Drives Funding Push 
SMIC Shares Rally as Q2 Profit Surges 262% on Strong Chip Demand 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Tesla Roadster Reveal Could Feature SpaceX Thrusters in August 
Synlait Milk Denies Fonterra, a2 Milk Takeover Talks 
Thyssenkrupp Raises 2026 Profit Outlook as Steel and Materials Units Strengthen 
Bernstein Picks BYD and Xiaomi as Top China EV Stocks Despite Weaker Demand 
Australia’s Corporate Leaders Face Parliament Over KPMG Client Data Scandal 
Alcohol is one of the most dangerous drugs, yet its presence is ubiquitous in social settings and celebrations 
RFK Jr. Orders Extended Hantavirus Quarantine for Cruise Passenger 
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Venezuela Earthquake Health Risks Rise as Disease Monitoring Intensifies 
CDC Expands Ebola Screening Efforts at U.S. Entry Points Amid Congo and Uganda Outbreak 
Antofagasta Shares Drop 5% as Miner Cuts 2026 Copper Production Forecast 
J.P. Morgan Upgrades SanDisk, Sets $2,250 Price Target on AI NAND Growth 
White House Seeks $1.4 Billion to Combat Growing Ebola Outbreak 
Micron Stock Upgraded to Buy as New Street Sees $2 Trillion Valuation Potential 
Add as a preferred source on Google
AstraZeneca has discontinued a late-stage clinical trial evaluating volrustomig combined with chemotherapy for patients with metastatic non-small cell lung cancer (NSCLC), dealing another setback to the pharmaceutical giant’s drug development pipeline.
The company said Monday that it stopped the Phase III eVOLVE-Lung02 trial following a recommendation from an independent data monitoring committee. The committee concluded that the volrustomig combination was unlikely to achieve the study’s primary endpoints of improving progression-free survival (PFS) or overall survival (OS).
The trial focused on patients whose tumors lacked PD-L1 expression and compared the experimental treatment with the study’s control arm.
Despite the disappointing efficacy findings, AstraZeneca reported no unexpected safety issues. The safety profile observed with volrustomig and chemotherapy remained consistent with the known profiles of the individual treatments, with no new safety concerns identified.
Susan Galbraith, AstraZeneca’s executive vice president of oncology hematology research and development, acknowledged the disappointing outcome while emphasizing that the company intends to apply lessons from the study to its ongoing efforts to develop new lung cancer treatments.
eVOLVE-Lung02 was a large global study involving 895 patients across 25 countries, highlighting the scale of AstraZeneca’s investment in testing volrustomig as a potential treatment for metastatic NSCLC.
The trial discontinuation adds to investor scrutiny of the AstraZeneca drug pipeline following several clinical setbacks this year. The company is pursuing an ambitious target of reaching $80 billion in annual revenue, making the performance of its late-stage pipeline increasingly important to its long-term growth strategy.
Another notable setback involved Wainua, developed with Ionis Pharmaceuticals. Earlier this year, results from the Phase III CARDIO-TTRansform study showed that the treatment failed to outperform placebo in reducing cardiovascular deaths among patients with a progressive and potentially fatal heart condition.
The latest failure underscores the uncertainty surrounding late-stage pharmaceutical development, even as AstraZeneca continues investing heavily in oncology, cardiovascular disease and rare-disease therapies.
